[go: up one dir, main page]

MX2019009386A - Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer. - Google Patents

Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer.

Info

Publication number
MX2019009386A
MX2019009386A MX2019009386A MX2019009386A MX2019009386A MX 2019009386 A MX2019009386 A MX 2019009386A MX 2019009386 A MX2019009386 A MX 2019009386A MX 2019009386 A MX2019009386 A MX 2019009386A MX 2019009386 A MX2019009386 A MX 2019009386A
Authority
MX
Mexico
Prior art keywords
cancer immunotherapy
subject
predict
clinical effect
cancer
Prior art date
Application number
MX2019009386A
Other languages
English (en)
Inventor
Kagamu Hiroshi
Original Assignee
Univ Saitama Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saitama Medical filed Critical Univ Saitama Medical
Publication of MX2019009386A publication Critical patent/MX2019009386A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a la predicción de la capacidad de respuesta a inmunoterapia del cáncer de un sujeto a base de la composición de células T del sujeto y un método terapéutico que usa inmunoterapia del cáncer en base a la predicción. La presente invención también proporciona un método para mejorar o mantener la capacidad de respuesta a inmunoterapia del cáncer de un sujeto. Solución al problema La capacidad de respuesta a inmunoterapia del cáncer se predice al determinar un valor relativo de una subpoblación de células T CD4+, subpoblación de células dendríticas, y/o subpoblación de células T CD8+ correlacionadas con una estimulación de células dendríticas en una respuesta inmune antitumoral en una muestra derivada de un sujeto. También se proporciona una composición para tratar o prevenir cáncer que comprende células tales como células T CD62LbajoCD4+.
MX2019009386A 2017-02-07 2018-02-06 Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer. MX2019009386A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017020685 2017-02-07
JP2017110069 2017-06-02
PCT/JP2018/004090 WO2018147291A1 (en) 2017-02-07 2018-02-06 Immunological biomarker for predicting clinical effect of cancer immunotherapy

Publications (1)

Publication Number Publication Date
MX2019009386A true MX2019009386A (es) 2019-11-05

Family

ID=61527481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009386A MX2019009386A (es) 2017-02-07 2018-02-06 Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer.

Country Status (13)

Country Link
US (3) US11293924B2 (es)
EP (2) EP3580569B1 (es)
JP (4) JP6664684B1 (es)
KR (2) KR102490278B1 (es)
CN (2) CN116712458A (es)
AU (1) AU2018218844B2 (es)
CA (1) CA3052027A1 (es)
IL (1) IL268524A (es)
MX (1) MX2019009386A (es)
SG (1) SG11201907102XA (es)
TW (2) TW202323820A (es)
UY (1) UY37594A (es)
WO (1) WO2018147291A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580569B1 (en) 2017-02-07 2022-03-09 Saitama Medical University Immunological biomarker for predicting clinical effect of cancer immunotherapy
AU2018333276B2 (en) * 2017-09-12 2025-04-17 ImmuneSignatures Pty Ltd Predicting responses to immunotherapy
JP2022512973A (ja) * 2018-11-09 2022-02-07 ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー 腫瘍微小環境の組成を測定するための方法及び組成物
JP7606225B2 (ja) * 2019-02-20 2024-12-25 学校法人 埼玉医科大学 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
CN113710274A (zh) * 2019-02-20 2021-11-26 学校法人埼玉医科大学 用于预测癌症免疫疗法中的长期存活的方法及组合物
EP3953712A1 (en) * 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
US20230019261A1 (en) * 2019-12-02 2023-01-19 Temple University-Of The Commonwealth System Of Higher Education Combinatorial MAP Antibody Tests for Detection and Diagnosis
AU2021260997A1 (en) * 2020-04-21 2022-12-22 Kiadis Pharma Intellectual Property B.V. Methods and system for validating flow cytometry measurements
JP6796737B1 (ja) * 2020-06-02 2020-12-09 振武 曽 多項目自動血球計数装置
EP4212174A4 (en) 2020-09-08 2024-09-11 Saitama Medical University Biomarker for predicting response to cancer treatment
CN112114129B (zh) * 2020-09-25 2025-11-11 苏州尔生生物医药有限公司 肿瘤特异性t细胞的检测方法
AU2020469045A1 (en) * 2020-09-25 2023-04-27 Suzhou Ersheng Biopharmaceutical Co., Ltd Detection method for tumor-specific t cells
JP2023553569A (ja) * 2020-12-15 2023-12-22 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク Ｓｑｓｔｍ１及びがん治療におけるその使用
WO2022215843A1 (ko) * 2021-04-06 2022-10-13 (주)에스엠티바이오 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법
WO2023083924A1 (en) * 2021-11-10 2023-05-19 Institut Gustave Roussy Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapy
CN114354931B (zh) * 2021-12-14 2023-03-14 南方医科大学南方医院 脾肿大在确定肿瘤患者免疫检查点抑制剂治疗疗效中的应用
US12013816B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Querying metadata in a storage system
US12013857B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Identifying hot items in a distributed storage system
WO2023230548A1 (en) * 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2024185887A1 (ja) * 2023-03-08 2024-09-12 イミュニティリサーチ株式会社 細胞集団を特定するためのシステム、方法、およびプログラム
JP7368678B1 (ja) 2023-04-26 2023-10-25 イミュニティリサーチ株式会社 Ｃｄ４＋ｔ細胞集団中の特定の細胞亜集団の相対量の測定方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP2006280307A (ja) * 2005-04-01 2006-10-19 Kyoto Univ 制御性ｔ細胞の製造方法
CN101346463B (zh) * 2005-12-21 2012-06-13 江苏太瑞生诺生物医药科技有限公司 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法
US20090258025A1 (en) 2007-07-13 2009-10-15 Genentech, Inc. Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
JP6230208B2 (ja) 2007-11-08 2017-11-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
US9176122B2 (en) * 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20120088678A1 (en) * 2010-09-08 2012-04-12 Sanford-Burnham Medical Research Institute Method for prediction of response to rheumatoid arthritis therapeutics
SG193591A1 (en) * 2011-03-23 2013-10-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
AU2012279225A1 (en) 2011-07-01 2014-01-16 Beckman Coulter, Inc. Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
CA2883577A1 (en) * 2012-09-04 2014-03-13 Niigata University Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
EP2892558B1 (en) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
WO2014140856A2 (en) * 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
WO2015061796A1 (en) * 2013-10-25 2015-04-30 Nodality Inc. Methods and compositions for immunomodulation
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
US9586056B2 (en) 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
EA034921B1 (ru) 2014-09-28 2020-04-07 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Модуляция стимулирующих и нестимулирующих миелоидных клеток
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
US20190282632A1 (en) 2014-10-23 2019-09-19 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CA2982984C (en) 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
US10532056B2 (en) 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US11385231B2 (en) 2015-08-27 2022-07-12 Inserm (Institut National De La Sante Et De La Recherche Scientifique) Methods for predicting the survival time of patients suffering from a lung cancer
WO2017140826A1 (en) 2016-02-18 2017-08-24 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
WO2018140644A1 (en) 2017-01-25 2018-08-02 Musc Foundation For Research Development Modified t cells and uses thereof
US20200049714A1 (en) 2017-02-06 2020-02-13 Novartis Ag Method of predicting response to immunotherapy
EP3580569B1 (en) 2017-02-07 2022-03-09 Saitama Medical University Immunological biomarker for predicting clinical effect of cancer immunotherapy
US20200393469A1 (en) 2017-05-16 2020-12-17 Kurume University Method for determining eligibility of brain tumor patient for tailor-made type peptide vaccine agent

Also Published As

Publication number Publication date
CN116712458A (zh) 2023-09-08
US11293924B2 (en) 2022-04-05
JP2020512530A (ja) 2020-04-23
US20220178933A1 (en) 2022-06-09
CN110446928A (zh) 2019-11-12
US20230349909A1 (en) 2023-11-02
JP2020073924A (ja) 2020-05-14
EP4039260A1 (en) 2022-08-10
JP2022105066A (ja) 2022-07-12
SG11201907102XA (en) 2019-08-27
WO2018147291A1 (en) 2018-08-16
CA3052027A1 (en) 2018-08-16
EP3580569B1 (en) 2022-03-09
KR20190112027A (ko) 2019-10-02
TW202323820A (zh) 2023-06-16
JP6664684B1 (ja) 2020-03-13
US12298311B2 (en) 2025-05-13
IL268524A (en) 2019-09-26
EP3580569A1 (en) 2019-12-18
UY37594A (es) 2018-08-31
CN110446928B (zh) 2023-06-20
TW201833551A (zh) 2018-09-16
JP7067804B2 (ja) 2022-05-16
TWI795386B (zh) 2023-03-11
KR102490278B1 (ko) 2023-01-18
EP4039260B1 (en) 2024-04-17
US20200025768A1 (en) 2020-01-23
JP7781419B2 (ja) 2025-12-08
AU2018218844B2 (en) 2024-08-01
KR20230017355A (ko) 2023-02-03
AU2018218844A1 (en) 2019-09-19
KR102617574B1 (ko) 2023-12-22
JP2024023862A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
MX2019009386A (es) Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer.
PH12020500677A1 (en) Neoantigens and uses thereof
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
MX2018002610A (es) Anticuerpos anti-lag-3.
BR112017006710A2 (pt) vetor de expressão de car e células t expressando car
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
SG10201810723VA (en) Improved t cell compositions
BR112017013981A2 (pt) receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2023006039A (es) Celulas inmunes defectuosas para suv39h1.
UY36289A (es) ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN
BR112014009276A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
BR112021021608A2 (pt) Células car-t direcionadas a cd19 específicas para antígeno
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112016023523A2 (pt) produtos de células t modificados em gene de composição definida
ES2851123T1 (es) Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
BR112017008693A2 (pt) célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
MX2017000646A (es) Celulas geneticamente modificadas para terapia celular adoptiva.
MX380176B (es) Molecula ligada a antigeno inmunoactivada.
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
BR112016024957A2 (pt) métodos aperfeiçoados para fabricação de terapias celulares adotivas
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.